Skip to main content
. Author manuscript; available in PMC: 2019 Apr 20.
Published in final edited form as: Sci Signal. 2018 Sep 11;11(547):eaau5147. doi: 10.1126/scisignal.aau5147

Fig. 6. Efficacy of CK2 inhibitors against MB in vivo.

Fig. 6.

(A) Experimental scheme for flank and cerebellar tumor trials. Blue triangle, treatment. (B and C) Relative tumor growth of Ptch+/−;Tpr53−/− (B) and Ptch+/−;Tpr53−/−;SmoD477G (C) MB flank allografts. Data are means ± SD; P values by a two-tailed t test. (D) Representative picture of mice treated with TBB versus GDC-0449. Dashed line demarcates the tumor. (E) Kaplan-Meier survival analysis of mice with Ptch+/−;Tpr53−/−;SmoD477G MB cerebellar allografts treated with CX-4945 or vehicle control. n = 7 mice in each treatment group. (F) Kaplan-Meier analysis of CK2 gene expression and overall survival in human patients (n = 179) with SHH-subtype MB. P values in (E) and (F) were determined by a log-rank Mantel-Cox test.